Objectif
Biomarkers in discovery are valuable tools to understand the pathobiology of a disease and the pharmacology of a target under investigation. In-vitro screen would be invaluable in identifying working hypothesis early in drug development process. Information provided by properly selected biomarkers can greatly influence a go/no go decision. The challenge is to identify relevant biomarkers early enough to implement them for such critical decisions.
In developing in-vitro assays to identify biomarkers with potential clinical application and utility, a clear understanding and determination of what that biomarker will assess must be defined. More reliable biomarker screening protocols based on allometric scaling laws are needed to be implemented in order to gain results more respondent to human physiology. The predictive power of High Content Screening techniques can be enhanced by working with primary cells or differentiated stem cells and in 3-D culture. Nevertheless, in-vitro cell cultures are still far away from the complexity of human tissues or organs.
IVTech intends to industrialize and test Multidyn, a patented advanced low-cost cell culture system made up by a 24-chambers plate complying with the multiwell standard, capable of any internal connection and flow within the cells, able to realize cheaper faster in-vitro physiologically relevant cellular systems. Multidyn will be tested for early diabetes biomarker discovery by using a developed model of liver, vascular endothelium and adipose tissues, and when equipped with the highly performing 3D scaffolds provided by the partner Scaffdex and with suitable High Content Imaging systems provided by the partner Celltool and selected scientific laboratories.
IVTech’ Multidyn is at TRL 6. Phase 1 project will assess the activities needed to demonstrate the product in operational environment with potential end-users, establish a large scale production and test the market.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicinepathology
- medical and health sciencesbasic medicinephysiology
Programme(s)
Thème(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
55054 Massarosa
Italie
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.